GSK plc (LON:GSK – Get Free Report) has been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is GBX 2,034.29.
A number of equities analysts have recently weighed in on the company. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Citigroup lowered their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Tuesday, April 14th. Shore Capital Group reissued a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,900 price target on shares of GSK in a research report on Wednesday.
GSK Price Performance
GSK (LON:GSK – Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%.The company had revenue of GBX 762.90 billion for the quarter. Sell-side analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.
Insider Activity at GSK
In related news, insider Jonathan Symonds purchased 5,000 shares of the stock in a transaction that occurred on Friday, March 20th. The stock was acquired at an average cost of GBX 1,951 per share, with a total value of £97,550. Also, insider Wendy Becker purchased 4,000 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was bought at an average cost of GBX 1,963 per share, with a total value of £78,520. In the last three months, insiders purchased 9,619 shares of company stock valued at $19,452,794. 0.20% of the stock is owned by insiders.
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.
See Also
- Five stocks we like better than GSK
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.
